# US 2026/0265722 A1 · Improved method of purifying botulinum toxin using multimodal chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265722 A1
- Document ID: US20260265722A1
- Status: Published application
- Kind: A1
- Application number: 19/165,714
- Filed: 2023-03-16
- Published: 2026-09-10
- Earliest claimed: 2023-03-16
- Applicants: Daewoong Co., Ltd.
- Inventors: Yong In SO; Min A LEE; Sung Soo KIM; Sang Eun JEON; Ji Seong PARK; Seung Jung CHOO; Se Mi KIM; Yu Jin KANG; Kyoung Yun KIM
- Web page: https://patentgrep.com/patent/US20260265722A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- C07K 1/16: by chromatography
- C07K 1/165: {mixed-mode chromatography}
- C07K 1/18: Ion-exchange chromatography
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed is a method of purifying botulinum toxin including purifying botulinum toxin from a sample containing botulinum toxin using multimodal chromatography and purifying the botulinum toxin using cation exchange chromatography. The method of purifying botulinum toxin enables purification of botulinum toxin with a high purity of 99% or more and high yield, and thus is useful for botulinum toxin production.

## Claims

### Claim 1

A method of purifying botulinum toxin comprising:
(a) purifying botulinum toxin from a sample containing botulinum toxin using anion exchange chromatography (AEX), hydrophobic interaction chromatography (HIC), and size exclusion chromatography (SEC); and
(b) purifying the botulinum toxin using cation exchange chromatography.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step (a) is performed using a multimodal resin having functions of anion exchange chromatography, hydrophobic interaction chromatography, and size exclusion chromatography.

### Claim 3 (depends on 1)

The method according to claim 1, wherein step (a) comprises purifying a fraction containing botulinum toxin purified using the multimodal resin having functions of anion exchange chromatography and hydrophobic interaction chromatography, using size exclusion chromatography.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the botulinum toxin in the multimodal chromatography in step (a) flows through the multimodal chromatography resin, rather than binding to the multimodal chromatography resin.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the botulinum toxin in the cation exchange chromatography in step (b) binds to a cation exchange resin and is then eluted.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the sample containing the botulinum toxin in step (a) is a culture solution of a Clostridium botulinum strain, a lysate thereof, or a precipitate thereof.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising filtration.

### Claim 8 (depends on 1)

The method according to claim 1, further comprising:
(i) depth-filtering a sample containing botulinum toxin; and
(ii) ultrafiltering the depth-filtered sample.

### Claim 9 (depends on 8)

The method according to claim 8, wherein step (ii) is performed by tangential flow filtration (TFF).

### Claim 10 (depends on 1)

The method according to claim 1, wherein a finally purified botulinum toxin has a purity of 99% or higher.

### Claim 11 (depends on 1)

A composition comprising botulinum toxin purified by the method according to claim 1.

### Claim 12 (depends on 3)

The method according to claim 3, wherein the botulinum toxin in the multimodal chromatography in step (a) flows through the multimodal chromatography resin, rather than binding to the multimodal chromatography resin.
